ReviewClinical pharmacology : advances and applications2014
Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.
Review in Clinical pharmacology : advances and applications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.International journal of hematology · 2016Trial
- Integrating resistance biology, virulence networks, and precision therapeutics against multidrug-resistant Pseudomonas aeruginosa.Infection · 2026Review
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Structure-function comparison of Arbekacin with other aminoglycosides elucidates its higher potency as bacterial translation inhibitor.Scientific reports · 2025Article
- Effects of thiram exposure on liver metabolism of chickens.Frontiers in veterinary science · 2023Article
- The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic.European respiratory review : an official journal of the European Respiratory Society · 2022Article
- Molecular Basis of Non-β-Lactam Antibiotics Resistance inAntibiotics (Basel, Switzerland) · 2022Review
- Identification and antimicrobial susceptibility profiles of Nocardia species clinically isolated in Japan.Scientific reports · 2021Article
- Mechanistic insights into translation inhibition by aminoglycoside antibiotic arbekacin.Nucleic acids research · 2021Article
- Bacterial Targets of Antibiotics in Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.Antimicrobial agents and chemotherapy · 2020Article
- Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.Microorganisms · 2020Review
- Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution.Antimicrobial agents and chemotherapy · 2019Article
- Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation.EcoSal Plus · 2018Review
- In vitro and in vivo antimicrobial activity of TS2037, a novel aminoglycoside antibiotic.The Journal of antibiotics · 2018Article
- Expanding Aminoglycoside Resistance Enzyme Regiospecificity by Mutation and Truncation.Biochemistry · 2016Article
- Aminoglycosides: An Overview.Cold Spring Harbor perspectives in medicine · 2016Review
- Clinical Usefulness of Arbekacin.Infection & chemotherapy · 2016Review
- Pseudomonas aeruginosa ventilator-associated pneumonia management.Infection and drug resistance · 2016Review
- Detecting 16S rRNA Methyltransferases in Enterobacteriaceae by Use of Arbekacin.Journal of clinical microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes. ABK shows broad antimicrobial activities against not only Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) but also Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. ABK has been approved as an injectable formulation in Japan since 1990, under the trade name Habekacin, for the treatment of patients with pneumonia and sepsis caused by MRSA. The drug has been used in more than 250,000 patients, and its clinical benefit and safety have been proven over two decades. ABK currently shows promise for the application for the treatment of multidrug-resistant Gram-negative bacterial infections such as multidrug-resistant strains of P. aeruginosa and Acinetobacter baumannii because of its synergistic effect in combination with beta-lactams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.